127 related articles for article (PubMed ID: 1458463)
1. Biological and immunological features of humanized M195 (anti-CD33) monoclonal antibodies.
Caron PC; Co MS; Bull MK; Avdalovic NM; Queen C; Scheinberg DA
Cancer Res; 1992 Dec; 52(24):6761-7. PubMed ID: 1458463
[TBL] [Abstract][Full Text] [Related]
2. Murine and humanized constructs of monoclonal antibody M195 (anti-CD33) for the therapy of acute myelogenous leukemia.
Caron PC; Schwartz MA; Co MS; Queen C; Finn RD; Graham MC; Divgi CR; Larson SM; Scheinberg DA
Cancer; 1994 Feb; 73(3 Suppl):1049-56. PubMed ID: 8306247
[TBL] [Abstract][Full Text] [Related]
3. A phase 1B trial of humanized monoclonal antibody M195 (anti-CD33) in myeloid leukemia: specific targeting without immunogenicity.
Caron PC; Jurcic JG; Scott AM; Finn RD; Divgi CR; Graham MC; Jureidini IM; Sgouros G; Tyson D; Old LJ
Blood; 1994 Apr; 83(7):1760-8. PubMed ID: 8142644
[TBL] [Abstract][Full Text] [Related]
4. Chimeric and humanized antibodies with specificity for the CD33 antigen.
Co MS; Avdalovic NM; Caron PC; Avdalovic MV; Scheinberg DA; Queen C
J Immunol; 1992 Feb; 148(4):1149-54. PubMed ID: 1737932
[TBL] [Abstract][Full Text] [Related]
5. Radiolabeled anti-CD33 monoclonal antibody M195 for myeloid leukemias.
Jurcic JG; Caron PC; Nikula TK; Papadopoulos EB; Finn RD; Gansow OA; Miller WH; Geerlings MW; Warrell RP; Larson SM
Cancer Res; 1995 Dec; 55(23 Suppl):5908s-5910s. PubMed ID: 7493368
[TBL] [Abstract][Full Text] [Related]
6. Humanized M195 monoclonal antibody conjugated to recombinant gelonin: an anti-CD33 immunotoxin with antileukemic activity.
Pagliaro LC; Liu B; Munker R; Andreeff M; Freireich EJ; Scheinberg DA; Rosenblum MG
Clin Cancer Res; 1998 Aug; 4(8):1971-6. PubMed ID: 9717827
[TBL] [Abstract][Full Text] [Related]
7. Anti-CD33 monoclonal antibody M195 for the therapy of myeloid leukemia.
Caron PC; Scheinberg DA
Leuk Lymphoma; 1993; 11 Suppl 2():1-6. PubMed ID: 8124221
[TBL] [Abstract][Full Text] [Related]
8. Genetically engineered deglycosylation of the variable domain increases the affinity of an anti-CD33 monoclonal antibody.
Co MS; Scheinberg DA; Avdalovic NM; McGraw K; Vasquez M; Caron PC; Queen C
Mol Immunol; 1993 Oct; 30(15):1361-7. PubMed ID: 8232322
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-2 enhancement of cytotoxicity by humanized monoclonal antibody M195 (anti-CD33) in myelogenous leukemia.
Caron PC; Lai LT; Scheinberg DA
Clin Cancer Res; 1995 Jan; 1(1):63-70. PubMed ID: 9815888
[TBL] [Abstract][Full Text] [Related]
10. Restricted expression of an early myeloid and monocytic cell surface antigen defined by monoclonal antibody M195.
Tanimoto M; Scheinberg DA; Cordon-Cardo C; Huie D; Clarkson BD; Old LJ
Leukemia; 1989 May; 3(5):339-48. PubMed ID: 2716349
[TBL] [Abstract][Full Text] [Related]
11. Characterization of murine and humanized anti-CD33, gelonin immunotoxins reactive against myeloid leukemias.
McGraw KJ; Rosenblum MG; Cheung L; Scheinberg DA
Cancer Immunol Immunother; 1994 Dec; 39(6):367-74. PubMed ID: 8001024
[TBL] [Abstract][Full Text] [Related]
12. Monoclonal antibody M195: a diagnostic marker for acute myelogenous leukemia.
Scheinberg DA; Tanimoto M; McKenzie S; Strife A; Old LJ; Clarkson BD
Leukemia; 1989 Jun; 3(6):440-5. PubMed ID: 2725060
[TBL] [Abstract][Full Text] [Related]
13. Antileukemic activity of recombinant humanized M195-gelonin immunotoxin in nude mice.
Xu Y; Xu Q; Rosenblum MG; Scheinberg DA
Leukemia; 1996 Feb; 10(2):321-6. PubMed ID: 8637241
[TBL] [Abstract][Full Text] [Related]
14. Alpha-emitting bismuth cyclohexylbenzyl DTPA constructs of recombinant humanized anti-CD33 antibodies: pharmacokinetics, bioactivity, toxicity and chemistry.
Nikula TK; McDevitt MR; Finn RD; Wu C; Kozak RW; Garmestani K; Brechbiel MW; Curcio MJ; Pippin CG; Tiffany-Jones L; Geerlings MW; Apostolidis C; Molinet R; Geerlings MW; Gansow OA; Scheinberg DA
J Nucl Med; 1999 Jan; 40(1):166-76. PubMed ID: 9935073
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy in acute myelogenous leukemia and myelodysplastic syndrome.
Matthews DC
Leukemia; 1998 Sep; 12 Suppl 1():S33-6. PubMed ID: 9777893
[TBL] [Abstract][Full Text] [Related]
16. A phase I trial of humanized monoclonal antibody HuM195 (anti-CD33) with low-dose interleukin 2 in acute myelogenous leukemia.
Kossman SE; Scheinberg DA; Jurcic JG; Jimenez J; Caron PC
Clin Cancer Res; 1999 Oct; 5(10):2748-55. PubMed ID: 10537338
[TBL] [Abstract][Full Text] [Related]
17. Elimination of human leukemia by monoclonal antibodies in an athymic nude mouse leukemia model.
Xu Y; Scheinberg DA
Clin Cancer Res; 1995 Oct; 1(10):1179-87. PubMed ID: 9815910
[TBL] [Abstract][Full Text] [Related]
18. Engineered humanized dimeric forms of IgG are more effective antibodies.
Caron PC; Laird W; Co MS; Avdalovic NM; Queen C; Scheinberg DA
J Exp Med; 1992 Oct; 176(4):1191-5. PubMed ID: 1402660
[TBL] [Abstract][Full Text] [Related]
19. Drug-resistant AML cells and primary AML specimens are killed by 111In-anti-CD33 monoclonal antibodies modified with nuclear localizing peptide sequences.
Kersemans V; Cornelissen B; Minden MD; Brandwein J; Reilly RM
J Nucl Med; 2008 Sep; 49(9):1546-54. PubMed ID: 18703602
[TBL] [Abstract][Full Text] [Related]
20. Calicheamicin-conjugated humanized anti-CD33 monoclonal antibody (gemtuzumab zogamicin, CMA-676) shows cytocidal effect on CD33-positive leukemia cell lines, but is inactive on P-glycoprotein-expressing sublines.
Naito K; Takeshita A; Shigeno K; Nakamura S; Fujisawa S; Shinjo K; Yoshida H; Ohnishi K; Mori M; Terakawa S; Ohno R
Leukemia; 2000 Aug; 14(8):1436-43. PubMed ID: 10942240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]